Safety and Efficacy of Palbociclib (CDK4/6 inhibitor) and Radiotherapy in Metastatic Breast Cancer Patients: Initial Results of a Novel Combination

被引：0
|
作者：
Chowdhary, M. [1 ]
Sen, N. [1 ]
Chowdhary, A. [2 ]
Usha, L. [1 ]
Cobleigh, M. [1 ]
Wang, D. [1 ]
Patel, K. [3 ]
Barry, P. N., Jr. [1 ]
Rao, R. [1 ]
机构：
[1] Rush Univ, Med Ctr, Chicago, IL 60612 USA
[2] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[3] Yale Sch Med, New Haven, CT USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2019年 / 105卷 / 01期
关键词：
D O I：
10.1016/j.ijrobp.2019.06.619
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2002
引用
收藏
页码：E2 / E2
页数：1
相关论文
共 50 条
  • [31] CDK4/6 Inhibitors in the Treatment of Metastatic Breast Cancer
    Ettl, Johannes
    Huober, Jens
    Lueftner, Diana
    Marme, Frederik
    Wuerstlein, Rachel
    BREAST CARE, 2017, 12 (02) : 118 - 120
  • [32] Liquid biopsies to predict CDK4/6 inhibitor efficacy and resistance in breast cancer
    Main, Sasha C.
    Cescon, David W.
    Bratman, Scott, V
    CANCER DRUG RESISTANCE, 2022, 5 (03) : 727 - 748
  • [33] Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer
    Lee, Cha Len
    Cremona, Mattia
    Farrelly, Angela
    Workman, Julie A.
    Kennedy, Sean
    Aslam, Razia
    Carr, Aoife
    Madden, Stephen
    O'Neill, Brian
    Hennessy, Bryan T.
    Toomey, Sinead
    CANCER BIOLOGY & THERAPY, 2023, 24 (01)
  • [34] Optimizing the combination of the CDK4/6 inhibitor palbociclib and paclitaxel using cell cycle analysis
    Spencer, Jade A.
    Race, Amanda D.
    Cooper, Patricia A.
    Shnyder, Steven D.
    Loadman, Paul M.
    Twelves, Christopher J.
    CANCER RESEARCH, 2020, 80 (16)
  • [35] CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer
    Zhang, Kai
    Hong, Ruoxi
    Kaping, Lee
    Xu, Fei
    Xia, Wen
    Qin, Ge
    Zheng, Qiufan
    Lu, Qianyi
    Zhai, Qinglian
    Shi, Yanxia
    Yuan, Zhongyu
    Deng, Wuguo
    Chen, Miao
    Wang, Shusen
    CANCER LETTERS, 2019, 447 : 130 - 140
  • [36] Metabolic reprogramming of ER plus breast cancer cells in response and resistance to the CDK4/6 inhibitor palbociclib
    Lorito, Nicla
    Bacci, Marina
    Smiriglia, Alfredo
    Parri, Matteo
    Malorni, Luca
    Di Leo, Angelo
    Chiarugi, Paola
    Morandi, Andrea
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 529 - 530
  • [37] Clinical development of CDK4/6 inhibitor for breast cancer
    Iwata, Hiroji
    BREAST CANCER, 2018, 25 (04) : 402 - 406
  • [38] Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib
    Miettinen, Teemu P.
    Peltier, Julien
    Hartlova, Anetta
    Gierlinski, Marek
    Jansen, Valerie M.
    Trost, Matthias
    Bjorklund, Mikael
    EMBO JOURNAL, 2018, 37 (10):
  • [39] Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer
    Patnaik, Amita
    Rosen, Lee S.
    Tolaney, Sara M.
    Tolcher, Anthony W.
    Goldman, Jonathan W.
    Gandhi, Leena
    Papadopoulos, Kyriakos P.
    Beeram, Muralidhar
    Rasco, Drew W.
    Myrand, Scott P.
    Kulanthaivel, Palaniappan
    Li, Lily
    Frenzel, Martin
    Cronier, Damien M.
    Chan, Edward M.
    Flaherty, Keith T.
    Wen, Patrick Y.
    Shapiro, Geoffrey I.
    CANCER RESEARCH, 2014, 74 (19)
  • [40] Clinical development of CDK4/6 inhibitor for breast cancer
    Hiroji Iwata
    Breast Cancer, 2018, 25 : 402 - 406
12345